Bicycle says BT8009 exhibits potential best-in-class ant-tumor activivity 11/08/22 BCYC Bicycle Therapeutics announced updates from the Phase I/II trial of BT8009 in patients with numerous cancer types where Nectin-4 is expressed. BT8009 is a potential first in class Bicycle Toxin Conjugate BTC targeting Nectin-4, a protein located on the surface of cells that is highly expressed in urothelial cancer and other solid tumors. "Dosing our first patient in the Phase II expansion portion of the BT8009 trial is a key development milestone for Bicycle," said Kevin Lee, Ph.D., Chief Executive Officer. "Based on the data presented to date, we believe we are making an important step towards hopefully providing a clinically meaningful, differentiated therapy compared to what is currently available for UC as well as for other tumors that express Nectin-4, such as non-small cell lung cancer." "The results from the Phase I dose escalation portion of the BT8009 Phase I/II trial are very encouraging and we are excited to move rapidly forward with the dose expansion portion of the trial," said Dominic Smethurst, MRCP, Chief Medical Officer of Bicycle Therapeutics. "BT8009 continues to exhibit potential best-in-class anti-tumor activity and a favorable tolerability profile, with a confirmed overall response rate from the latest cohorts consistent with previous findings from the trial, and we are pleased to see UC patients at the 5mg/m2 dose remaining on therapy and continuing to respond. We are also pleased to report a confirmed partial response in an NSCLC patient and look forward to providing additional data from the Phase I escalation cohorts at a medical meeting in the first half of 2023." WELCOME TO THE FIRST HALF OF 2023
THE STREET SEEMS TO THINK BCYC SHOULD LEVEL OUT IN THE $40'S> Bicycle Therapeutics initiated with a Buy at EF Hutton 01/04 BCYC EF Hutton analyst Tony Butler initiated coverage of Bicycle Therapeutics with a Buy rating and $55 price target. PIPER SANDLER- T $48 JMP SECURITIES T $46 With four products in the clinic advancing through dose-ranging studies or already in phase 2, having multiple partnerships with the potential to provide non-dilutive capital, and given its strong cash position of $361.5M, BCYC represent a unique opportunity, CAN THEY CATCH INVESTORS EYE THIS WEEK....
I'm depressed now. I have been listening to my first podcast. It is these three guys comedians/ actors who got together during Covid with the Zoom and created a podcast. It seemed so pure. These fakers. Will Arnet who is really funny and the other guy from Will & Grace and the director/ actor from Ozarks... So one guy brings a guest on and the other two riff of it. They know everyone in hollywood and the interviews are really fresh and different. It makes you forget about the news and whats going on in the real world and the name of the Podcast is Smartless... ... and I was happy. I listened to a whole bunch in a row. Then I learned amazon paid these guys $36 mil and It just ruined everything.
China is acting like N Korea. I doubt the head guy is even in charge anymore... This stinks- and should be punished....
Put a pin in this-- Defense Stocks- No more cuts to budget because of Balloon scare // We need to monitor low altitude threats better-- Can drone tech work-? Yes.
Good Morning GM What they are not telling you: The debt ceiling debate just got a lot messier. Republicans had a bunch of programs they wanted to cut from military. The cynic would say this is to weaken our own forces as one of Trump's old military guys penned a stroy calling for a 1/2 reduction in defense spending... And free Borsch to invading Russians! But behind the scenes this radical Repubs they wanted to cut defense and then if course turn around and blame Biden for cutting defense but the scary thing Joe was coming to the table because other cuts are just to difficult. Suddenly Defense spending is Off the table <--- Thank you China! Dummies! Now there is so very little to work with. If Social security is off the table.. and military this leaves a very small slice off funding (I'm guessing 15%) to find cuts in and this means the overall effort to make a deal for the debt ceiling is now much harder.
--Fastly upgraded to Buy from Underperform at BofA 06:04 FSLY Fastly double upgraded to Buy at BofA on intermediate-term potential 06:29 FSLY --Spirit AeroSystems price target raised to $50 from $42 at Barclays » 06:18 SPR --Toast price target raised to $30 from $26 at KeyBanc 06:19 TOST --Terex price target raised to $56 from $38 at Barclays » 06:20 TEX --Terex price target raised to $59 from $50 at Credit Suisse » 06:22 TEX --Protolabs upgraded to Buy from Hold at Benchmark 06:22 PRLB --Salesforce price target raised to $200 from $180 at BofA 06:55 CRM --Monday.com seesFY23 revenue $$688M-$693M , consensus $661.74M » 07:10 MNDY Ritchie Bros. sees Q4 revenue $444M, consensus $410.57M 07:11 RBA Teradata reports Q4 EPS 35c, consensus 30c 07:12 TDC Corsair Gaming price target raised to $19 from $16 at Baird 07:15 CRSR Hookipa Pharma achieves $10M milestone payment under Roche collaboration » 07:09 HOOK
Focus-> Teradata Corporation (TDC) NYSE - NYSE Delayed Price. 34.27-0.80(-2.28%) At close: 04:00PM EST 36.45+2.18(+6.36%)<-------------- Pre-Market:08:15AM EST